Assessing the ability of cardiovascular disease risk calculators to evaluate effectiveness of trials and interventions

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 6, Issue 4, 2006, Pages 417-424

  Finkelstein, Eric A ^a   Khavjou, Olga A ^a   Will, Julie C ^b   Farris, Rosanne P ^b   Prabhu, Malavika ^a  

^a RTI INTERNATIONAL   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

CHD CVD risk calculator; Risk assessment; Trial evaluation and effectiveness; WISEWOMAN

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

AGE; ALGORITHM; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE; MORTALITY; PROBABILITY; RISK ASSESSMENT; RISK REDUCTION; SIMULATION; SMOKING; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

EID: 33748098891     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.6.4.417     Document Type: Article

References (32)

1. American Heart Association. Heart Disease and Stroke Satistics: 2003 update. TX, USA: American Heart Association (2002).
2. Sellers DE, Crawford SL, Bullock K, McKinlay JB. Understanding the variability in the effectiveness of community heart health programs: a meta-analysis. Soc. Sci. Med. 44(9), 1325-1339 (1997).
3. Weinehall L, Lewis C, Nafziger AN et al. Different outcomes for different interventions with different focus! A cross-country comparison of community interventions in rural Swedish and US populations. Scand. J. Public Health 29(suppl. 56), 46-58 (2001).
4. Gomel MK, Olderburg B, Simpson JM, Chilvers M, Owen N. Composite cardiovascular risk outcomes of a worksite intervention trial. Am. J. Public Health 87(4), 673-676 (1997).
5. Finkelstein EA, Wittenborn JS, Farris RP. Evaluation of public health demonstration programs: the effectiveness and cost-effectiveness of WISEWOMAN. J. Womens Health 13(5), 625-633 (2004).
6. Finkelstein EA, Troped PJ, Will JC, Palombo R. Cost-effectiveness of a cardiovascular disease risk reduction program aimed at financially vulnerable women: the Massachusetts WISEWOMAN project. J. Womens Health Gend Based Med. 6, 519-526 (2002).
7. Will JC, Massoudi B, Mokdad A et al. Reducing risk for cardiovascular disease in uninsured women: combined results from two WISEWOMAN projects. J. Am. Med. Women's Assoc. 56(4), 161-165 (2001).
8. Winkleby MA, Feldman HA, Murray DM. Joint analysis of three US community intervention trials for reduction of cardiovascular disease risk. J. Clin. Epidemiol. 50(6), 645-658 (1997).
9. Simpson SH, Johnson JA, Tsuyuki RT. Economic impact of community pharmacist intervention in cholesterol risk management: an evaluation of the study of cardiovascular risk intervention by pharmacists. Pharmacotherapy 21(5), 627-635 (2001).
10. Grieve R, Hutton J, Green C. Selecting methods for the prediction of future events in cost-effectiveness models: a decision-framework and example from the cardiovascular field. Health Policy 64, 311-324 (2003).
11. Leaverton PE, Sorlie PD, Kleinman JC et al. Representativeness of the Framingham risk model for coronary heart disease mortality: a comparison with a national cohort study. J. Chronic. Dis. 40(8), 775-784 (1987).
12. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk-factor categories. Circulation 97(18), 1837-1847 (1998).
13. Will JC, Farris RP Sanders CG, Stockmyer CK, Finkelstein EA. Health promotion interventions for disadvantaged women: overview of the WISEWOMAN Projects. J. Womens Health 13(5), 484-502 (2004).
14. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 100(13), 1481-1492 (1999).
15. Wallis EJ, Ramsay LE, Ul Haq I et al. Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. Br. Med. J. 320(7236), 671-676 (2000).
16. Anderson KM, Wilson PW. Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 83(1), 356-362 (1991).
17. Joint British recommendations on prevention of coronary disease in clinical practice: summary. British Cardiac Society, British Hyperlipidemia. Association, British Hypertension Society, British Diabetic Association. Br. Med. J. 320(7236), 705-708 (2000).
18. Jackson R. Updated New Zealand cardiovascular disease risk-benefit prediction guide. Br. Med. J. 320(7236), 709-710 (2000).
19. Conroy RM, Pyoralà K, Fitzgerald AP et al. SCORE project group. Estimation of 10 year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J. 24(11), 987-1003 (2003).
20. Avins AL, Browner WS. Improving the prediction of coronary heart disease to aid in the management of high cholesterol levels: what a difference a decade makes. JAMA 279(6), 445-449 (1998).
21. Haq IU, Ramsay LE, Jackson PR, Wallis EJ. Prediction of coronary risk for primary prevention of coronary heart disease: a comparison of methods. QJM92(7), 379-385 (1999).
22. Reynolds TM, Twomey P, Wierzbicki AS. Accuracy of cardiovascular risk estimation for primary prevention in patients without diabetes. J. Cardiovasc. Risk 9(4), 183-190 (2002).
23. Reynolds TM, Twomey P, Wierzbicki AS. Concordance evaluation of coronary risk scores: implications for cardiovascular risk screening. Curr. Med. Res. Opin. 20(6), 811-818 (2004).
24. Wierzbicki AS, Reynolds TM, Gill K, Alg S, Crook MA. A comparison of algorithms for initiation of lipid lowering therapy in primary prevention of coronary heart disease. J. Cardiovasc. Risk 7(1), 63-67 (2000).
25. Quaglini S. Stefanelli M, Boiocchi L, Campari F, Cavallini A, Micieli G. Cardiovascular risk calculators: understanding differences and realising economic implications. Int. J. Med. Inform. 74(2-4), 191-199 (2005).
26. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 286(2), 180-187 (2001).
27. Liao Y, McGee DL, Cooper RS. Prediction of coronary heart disease mortality in blacks and whites: pooled data from two national cohorts. Am. J. Cardiol. 84(1), 31-36 (1999).
28. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10 year follow-up of the PROspective CArdiovascular Munster (PROCAM) study. Circulation 105(3), 310-315 (2002).
29. D'Agostino RB, Russell MW, Huse DM et al. Primary and subsequent coronary risk appraisal: new results from the Framingham Study. Am. Heart J. 143(1), 21 (2002).
30. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents and adults, 1999-2002. JAMA. 291(23), 2847-2850 (2004).
31. Prentice AM. The emerging epidemic of obesity in developing countries. Int. J. Epidemiol. 35(1), 93-99 (2005).
32. Swan G. Findings from the latest National Diet and Nutrition Survey. Proc. Nutr. Soc. 63(4), 505-512 (2004).